{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:08Z","timestamp":1791809288253,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jiac.2020.09.028","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:19:00Z","timestamp":1602008340000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of latent tuberculosis infection in patients receiving biologic agents"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2214-6695","authenticated-orcid":false,"given":"Hayato","family":"Yamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-5231","authenticated-orcid":false,"given":"Arisa","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tomio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-2578","authenticated-orcid":false,"given":"Sachiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2020.09.028_bib1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2020.09.028_bib2","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","article-title":"Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection","volume":"386","author":"Rangaka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2020.09.028_bib3","unstructured":"World Health Organization. The end TB strategy. https:\/\/www.who.int\/tb\/strategy\/en\/(Accessed 16 May 2020)."},{"key":"10.1016\/j.jiac.2020.09.028_bib4","series-title":"WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment","year":"2020"},{"key":"10.1016\/j.jiac.2020.09.028_bib5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2020.09.028_bib6","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2020.09.028_bib7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2020.09.028_bib8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.jiac.2020.09.028_bib10","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","article-title":"Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?","volume":"41","author":"Ehlers","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.jiac.2020.09.028_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jiac.2020.09.028_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines","volume":"8","author":"Hasan","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2020.09.028_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2020.09.028_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2020.09.028_bib16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2020.09.028_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"Lee","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jiac.2020.09.028_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jmii.2017.04.001","article-title":"Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders \u2013 a retrospective cohort study in Taiwan","volume":"51","author":"Huang","year":"2018","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2020.09.028_bib19","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1756-185X.12708","article-title":"Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey","volume":"19","author":"Cantini","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0000000000000466","article-title":"Screening and treatment of latent tuberculosis among patients receiving biologic agents: a national and international survey of rheumatologists","volume":"23","author":"Tran","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jiac.2020.09.028_bib22","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/1756-185X.13190","article-title":"Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database","volume":"20","author":"Tomio","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib23","author":"The Tuberculosis Surveillance Center"},{"key":"10.1016\/j.jiac.2020.09.028_bib24","first-page":"127","article-title":"BCG vaccination and tuberculosis in Japan","volume":"13","author":"Rahman","year":"2003","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.jiac.2020.09.028_bib25","first-page":"683","article-title":"Revision of standards for tuberculosis care","volume":"89","year":"2014","journal-title":"Kekkaku"},{"key":"10.1016\/j.jiac.2020.09.028_bib26","first-page":"21","article-title":"Treatment guidelines for latent tuberculosis infection","volume":"89","year":"2014","journal-title":"Kekkaku"},{"key":"10.1016\/j.jiac.2020.09.028_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2020.09.028_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.15156","article-title":"Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: real-world data from 18 Japanese facilities","volume":"47","author":"Kaneko","year":"2020","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jiac.2020.09.028_bib29","first-page":"607","article-title":"Frequency and risk factors of severe liver dysfunction in isoniazid mono-therapy for latent tuberculosis infection","volume":"91","author":"Ito","year":"2016","journal-title":"Kekkaku"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20303482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20303482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:01:21Z","timestamp":1761159681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X20303482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1341321X20303482"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2020.09.028","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of latent tuberculosis infection in patients receiving biologic agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2020.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}